Antimicrobial resistance and treatment of community-acquired pneumonia.
This article discusses the problem of antimicrobial resistance and how it affects the management of community-acquired pneumonia (CAP). The discussion is limited to infection with Streptococcus pneumoniae and to the treatment of patients hospitalized in a medical ward or an intensive care unit because of pneumococcal CAP.
Mandell
Lionel A
LA
Division of Infectious Diseases, McMaster University, Henderson Site, 711 Concession Street, 40 Wing, 5th floor, Room 503, Hamilton, Ontario L8V 1C3, Canada. lmandell@mcmaster.cs
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D017714:Community-Acquired Infections / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D006801:Humans; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy*; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D000900:Anti-Bacterial Agents